

Invasive Meningococcal (*Neisseria meningitidis*) Case Report



Texas Department of State Health Services
Infectious Disease Control Unit
1100 W. 49th St., Austin, Texas 78756
ph: (512) 458-7676 fax: (512) 458-7616

PATIENT INFORMATION

Name: _____
Last First MI

Address: _____
Street City County Zip

() _____
Phone Birth Date Sex Race* Ethnicity: Hispanic or Latino
 Not Hispanic or Latino
 Unknown

*W = White; B = Black/African American; N = American Indian/Alaska Native; P = Native Hawaiian/Pacific Islander; A = Asian; O = Other; U = Unknown

Was the patient a college student? Yes No Unknown College _____ If yes, college year Fr. So. Jr. Sr.

MEDICAL INFORMATION

Physician Name Physician Phone

Hospitalized? Yes No Hospital Name _____
Admit Date Discharge Date

Onset Date ____/____/____ Type of Infection: Bacteremia Meningitis Septic Arthritis Osteomyelitis Pneumonia
 Cellulitis Pericarditis Osteomyelitis Other (Specify) _____

Outcome (check one): Died ____/____/____ Recovering Unknown
Date

Did the patient have underlying conditions? (check all that apply): Diabetes mellitus HIV AIDS Cochlear Implant Asthma
 Alcohol Abuse Injecting Drug User (IDU) Chronic Lung Disease (COPD) Current Smoker Malignancy (specify) _____

Other prior illness within two weeks of onset (specify) _____

How was the *Neisseria meningitidis* case identified? Culture from sterile site Clinical purpura fulminans Gram negative diplococci
 Positive antigen test Other (specify) _____

LABORATORY INFORMATION (please attach lab report if available)

Date Collected ____/____/____ Specimen Source: CSF Blood Other Sterile Site (specify): _____

Culture Other test (specify) _____ Result: _____

ALL ISOLATES FROM A STERILE SOURCE MUST BE SENT TO DSHS LAB FOR TYPING: Date sent to DSHS: ____/____/____

WHAT WAS THE SEROGROUP? A B C Y W135 Other: _____ Not Groupable Unknown

WAS ISOLATE TESTED FOR SUSCEPTIBILITY TO ANTIBIOTICS? Yes No Please indicate antibiotic resistance _____

VACCINE INFORMATION

Did the patient receive the polysaccharide meningococcal vaccine? Yes No Unknown

Did the patient receive the conjugate meningococcal vaccine? Yes No Unknown

Date given: ____/____/____ Vaccine Name/Manufacturer _____

EXPOSURE DATA

Did any member of the patient's household have a similar illness during the two weeks prior to onset? Yes No

Name: _____ DOB: ___/___/___ Relationship: _____ Date of Illness: ___/___/___

Total number of close contacts: _____ Number who were prophylaxed: _____ Date prophylaxed: ___/___/___

Did the patient attend/work at a day-care center/home during the two weeks days prior to onset? Yes No

Name of center/home: _____ Address: _____ Date last attended: ___/___/___

Total classroom contacts: ___Students ___Staff Number Prophylaxed: ___Students ___Staff

Did any other child in this center have a similar infection during the two weeks prior to onset? Yes Name _____ No

RECOMMENDATIONS FOR PROPHYLAXIS

THE FOLLOWING GROUPS OF INDIVIDUALS SHOULD RECEIVE CHEMOPROPHYLAXIS AFTER EXPOSURE TO MENINGOCOCCAL DISEASE

- All family contacts or household members who spend at least 8 hours a day with the case.
- Classroom contacts in the childcare center or childcare home attended by the case.
- Persons directly exposed to infectious oral secretions without personal protective equipment (PPE).
- Index case(s) should receive prophylaxis prior to discharge.

It is important that antimicrobial chemoprophylaxis be administered as soon as possible, ideally within 24 hours. Chemoprophylaxis given more than 14 days after exposure is of limited value.

When prophylaxis is indicated, it should be administered to all eligible contacts at the same time to eliminate the organism from the population. Prophylaxis should begin within 24 hours of diagnosis or strong suspicion of case. Culturing of contacts is not recommended. Prophylaxis should not substitute for close observation of case contacts for symptoms.

DRUGS AND DOSAGE RECOMMENDATIONS FOR MENINGOCOCCAL CHEMOPROPHYLAXIS

| DRUG | AGE GROUP | DOSAGE ¹ | DURATION |
|---------------|----------------------------------|---------------------|----------------|
| Rifampin | Infants (< 1 month) | 5 mg/kg q 12 hours | 2 days |
| | Children (≥ 1 month) | 10 mg/kg q 12 hours | 2 days |
| | Adults (≥ 18 years) ³ | 600 mg q 12 hours | 2 days |
| Ciprofloxacin | Adults (≥ 18 years) | 500 mg po | Single Dose |
| Ceftriaxone | Children (≤ 15 years) | 125 mg | Single IM Dose |
| | Individuals (> 15 years) | 250 mg | Single IM Dose |

1 – All doses are oral unless otherwise specified
 2 – Only given if organism is known to be sensitive
 3 – PREGNANT WOMEN SHOULD NOT TAKE RIFAMPIN OR CIPROFLOXACIN

COMMENTS

Reported by: _____ Phone: (____) _____ Date Reported: ___/___/___

Investigated by: _____ Investigation Start Date: ___/___/___

Agency: _____ Phone: (____) _____